In one study, researchers measured enterolactone -- the form lignans take in the blood -- in 1,140 postmenopausal women with breast cancer.
After six years of follow-up, compared to those with the lowest levels, women with the highest lignan levels were 42 percent more likely to have survived, and their cancer was similarly less likely to have progressed.